 |
市場調査レポート
商品コード
1452730
希少疾患治療の世界市場規模、シェア、成長分析、投与経路別、薬剤別 - 産業予測（2024-2031年）Global Rare Disease Treatment Market Size, Share, Growth Analysis, By Route of Administration(Oral, Injectable), By Drug(Biologics, Biosimilar) - Industry Forecast 2024-2031 |
||||||
| 希少疾患治療の世界市場規模、シェア、成長分析、投与経路別、薬剤別 - 産業予測（2024-2031年） |
|
出版日: 2024年03月09日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の希少疾患治療市場規模は、2022年に1,349億1,000万米ドルと評価され、2023年の1,521億8,000万米ドルから2031年には3,988億7,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは12.8%で推移する見通しです。
希少疾患治療市場は、少数の人しか罹患しない病気を扱う医薬品ビジネスの重要なセグメントです。これらの病気は、人口全体から見ると比較的少数であるため、希少疾患と呼ばれることが多く、その希少性と複雑性は研究開発の障壁となっています。希少疾患の累積有病率は膨大であり、その希少性にもかかわらず、全世界で数百万人が罹患しています。
支持や認知度の向上、遺伝学的・分子生物学的研究の改善、新規治療技術の創出など、数多くの理由が市場の拡大を後押ししています。ゲノミクスの進歩のおかげで精密医療が登場し、珍しい病気に罹患している個人のユニークな遺伝子プロファイルに対応した標的医薬品に新たな機会がもたらされています。さらに、希少疾患用医薬品の指定や優遇措置など、規制当局の支援策により、製薬企業が希少疾患用医薬品の開発に参加することが奨励されています。
業界を牽引するもう一つの重要な要因は、学術機関、研究センター、製薬企業間の協力です。患者擁護団体と製薬会社の官民パートナーシップや業界提携のおかげで、希少疾患の調査は急速に進んでいます。しかし、開発コストの高さ、臨床試験に参加できる患者数の少なさ、患者募集や診断の難しさなど、この分野には克服すべき障害がまだたくさんあります。にもかかわらず、希少疾患治療市場は、生命を変える治療法を最も必要とする人々に提供するという希望を持って成長しており、このような時に軽視される病気によって影響を受ける人々の生活を向上させることに専念していることを改めて示しています。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- セカンダリおよびプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主な投資の分析
- 主な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
希少疾患治療の世界市場：投与経路別
- 市場概要
- 経口
- 注射
- その他
希少疾患治療の世界市場：薬剤別
- 市場概要
- 生物製剤
- バイオシミラー
- 低分子
希少疾患治療の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Sanofi SA
- Johnson & Johnson
- AbbVie Inc.
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- AstraZeneca PLC
- Bristol Myers Squibb Company
The Global Rare Disease Treatment Market size was valued at USD 134.91 billion in 2022 and is poised to grow from USD 152.18 billion in 2023 to USD 398.87 billion by 2031, growing at a CAGR of 12.8 % in the forecast period (2024-2031).
The market for treatments for rare diseases includes an important segment of the pharmaceutical business that deals with illnesses that only a small number of people have. Since they affect a comparatively small population as a whole, these illnesses-often referred to as orphan diseases-present a barrier for research and development because of their rarity and complexity. The cumulative prevalence of rare diseases is enormous, affecting millions of people globally, despite their separate rarities.
Numerous reasons, such as growing advocacy and awareness, improvements in genetic and molecular research, and the creation of novel therapeutic techniques, are propelling the market's expansion. Thanks to advances in genomics, precision medicine has emerged, providing new opportunities for targeted medicines catered to the unique genetic profiles of individuals suffering from uncommon diseases. Additionally, pharmaceutical companies have been encouraged to participate in the development of drugs for rare diseases by supportive regulatory initiatives such orphan drug designations and incentives.
An other important factor driving the industry is cooperation among academic institutions, research centers, and pharmaceutical businesses. Research on rare diseases has advanced faster thanks to public-private partnerships and industry alliances between patient advocacy groups and pharmaceutical companies. But there are still a lot of obstacles in this sector to overcome, including the high cost of development, the small number of patients available for clinical trials, and difficulties with patient recruitment and diagnosis. In spite of this, the market for rare disease treatments is growing with the hope of providing life-altering treatments to those who require them most, reiterating the dedication to enhancing the lives of those impacted by these sometimes disregarded illnesses.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rare Disease Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Rare Disease Treatment Market Segmental Analysis
The therapeutic area, route of administration, drug, distribution channel, and region segments make up the global market for treatments for rare diseases. The market is divided into the following therapeutic areas: cancer, hematologic disorders, infectious diseases, metabolic disorders, endocrine disorders, neurological conditions, cardiovascular conditions, musculoskeletal conditions, and others. The market is divided into oral, injectable, and other segments based on the route of administration. The market is divided into three segments based on drugs: biologics, biosimilars, and small molecules. The market is divided into three segments based on the distribution channel: online pharmacy, specialty pharmacy, and hospital pharmacy.The market is divided into four regions: North America, Europe, Asia Pacific, and LAMEA.
Drivers of the Global Rare Disease Treatment Market
One important factor is the rising funding for research and development initiatives aimed at creating novel medicines for uncommon illnesses. Developments in personalized medicine, genetics, and biotechnology are opening up new avenues for medicinal development.
Restraints in the Global Rare Disease Treatment Market
One major obstacle is the high expense of research, clinical trials, and drug development for uncommon disorders. The small patient population makes it difficult to recoup these expenses, which drives up the cost of medications.
Market Trends of the Global Rare Disease Treatment Market
Developments in Precision Medicine: This rapidly developing discipline is making it possible to design tailored medicines for particular genetic mutations or molecular abnormalities that cause uncommon diseases. This method lessens side effects while increasing treatment efficacy.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Rare Disease Treatment Market by Route of Administration
- Market Overview
- Oral
- Injectable
- and Others
Global Rare Disease Treatment Market by Drug
- Market Overview
- Biologics
- Biosimilar
- and Small Molecule
Global Rare Disease Treatment Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vertex Pharmaceuticals Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
